# Tolerance and Effectiveness of C14 on HPV Infection

> **NCT06672653** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **MGB Pharma** · enrollment: 66 (estimated)

## Conditions studied

- HPV-induced Cancers
- HPV Infections
- HIV
- Cervical Cancers
- Trial
- C14
- Monoterpenoid Zinc Tetra-ascorbo-camphorate

## Interventions

- **DRUG:** The monoterpenoid zinc tetra-ascorbo-camphorate ("C14")
- **DRUG:** Distilled water group

## Key facts

- **NCT ID:** NCT06672653
- **Lead sponsor:** MGB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11-15
- **Primary completion:** 2025-03-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672653, "Tolerance and Effectiveness of C14 on HPV Infection". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06672653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*